CoChat

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Open access
Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Zhan, Yingqian A., Hasan, Maysun M., Chavan, Shweta S., Meng, Fanli, Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S., Chan, Joseph M., Ciampricotti, Metamia, Chow, Andrew, Offin, Michael, Ray-Kirton, Jordana, Egger, Jacklynn D., Bhanot, Umesh K., Linkov, Irina, Asher, Marina, Roehrl, Michael H., Ventura, Katia, Qiu, Juan, de Stanchina, Elisa, Chang, Jason C., Rekhtman, Natasha, Houck-Loomis, Brian, Koche, Richard P., Yu, Helena A., Sen, Triparna, Rudin, Charles M. · 2021 · Journal of Hematology & Oncology
Cited by 89

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC) histologic transformation in the context of acquired resistance to targeted inhibition of driver mutations. LUAD-to-LUSC transdifferentiation, occurring in up to 9% of EGFR-mutant patients relapsed on osimertinib, is associated with notably poor prognosis. We hypothesized that multi-parameter profiling of the components of mixed histology (LUAD/LUSC) tumors could provide insight into factors licensing lineage plasticity between these histologies. Methods: We performed genomic, epigenomics, transcriptomics and protein analyses of microdissected LUAD and LUSC components from mixed histology tumors, pre-/post-transformation tumors and reference non-transformed LUAD and LUSC samples. We validated our findings through genetic manipulation of preclinical models in vitro and in vivo and performed patient-derived xenograft (PDX) treatments to validate potential therapeutic targets in a LUAD PDX model acquiring LUSC features after osimertinib treatment. Results: Our data suggest that LUSC transdifferentiation is primarily driven by transcriptional reprogramming rather than mutational events. We observed consistent relative upregulation of PI3K/AKT, MYC and PRC2 pathway genes. Concurrent activation of PI3K/AKT and MYC induced squamous features in EGFR-mutant LUAD preclinical models. Pharmacologic inhibition of EZH1/2 in combination with osimertinib prevented relapse with squamous-features in an EGFR-mutant patient-derived xenograft model, and inhibition of EZH1/2 or PI3K/AKT signaling re-sensitized resistant squamous-like tumors to osimertinib. Conclusions: Our findings provide the first comprehensive molecular characterization of LUSC transdifferentiation, suggesting putative drivers and potential therapeutic targets to constrain or prevent lineage plasticity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-021-01186-z

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 89

Metadata

Authors
Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., Chan, J. M., Ciampricotti, M., Chow, A., Offin, M., Ray-Kirton, J., Egger, J. D., Bhanot, U. K., Linkov, I., Asher, M., Roehrl, M. H., Ventura, K., Qiu, J., de Stanchina, E., Chang, J. C., Rekhtman, N., Houck-Loomis, B., Koche, R. P., Yu, H. A., Sen, T., & Rudin, C. M.
Venue
Journal of Hematology & Oncology
Published
2021-10-16
Volume
14
Issue
1
Pages
170-170
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3206277552
Cited by
89
References
13
FWCI
7.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. https://app.cochat.ai/papers/10.1186/s13045-021-01186-z
The paper
Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., Chan, J. M., Ciampricotti, M., Chow, A., Offin, M., Ray-Kirton, J., Egger, J. D., Bhanot, U. K., Linkov, I., Asher, M., . . . Rudin, C. M. (2021). Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-021-01186-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.